Vedanta Biosciences
Vedanta Biosciences raises $108M Series D at $550M valuation
Vedanta Biosciences: Series D Funding Round
Vedanta Biosciences has successfully raised $108M in Series D funding, reaching a valuation of $550M.
Company Overview
Microbiome-derived therapeutics
Funding Details
The Series D round was led by Johnson & Johnson Innovation, with participation from Mitsui & Co, Puretech Health, Flagship Pioneering.
Company Information
- Headquarters: 501 Boylston Street, Boston, MA 02116
- Founded: 2010
- Employees: 150+
- Category: Biotech
Investment
Vedanta Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Johnson & Johnson Innovation: Verified investor in Series D
- Mitsui & Co: Verified investor in Series D
- Puretech Health: Verified investor in Series D
- Flagship Pioneering: Verified investor in Series D
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free